E2F3 and marginal zone lymphoma: OTX015 (birabresib) has demonstrated potent antiproliferative effects in panels of DLBCL, MCL, marginal zone lymphoma (MZL), and MM cell lines by suppressing E2F3 target genes and decreasing inflammatory markers and, finally, the tumor volume in xenografts [231].